Cyclarity Therapeutics is a pioneering brand on a mission to treat the underlying causes of age-related diseases. They specialize in developing easy-to-use drugs that combat common conditions like atherosclerosis, heart attacks, and strokes by addressing the root cause – a build-up of arterial plaque. Through their innovative technology, Cyclarity removes arterial plaque by clearing non-degradable cholesterol that accumulates within cells in the arterial walls.

Their long-term goal is to provide a simple and affordable preventive therapy for people worldwide. Cyclarity's products are based on novel derivatives of a well-known, safe compound, and they approach cardiovascular disease from a fresh perspective. They aim to cure age-related diseases by repairing existing damage, using simple, direct, and rationally designed drugs.

Their first breakthrough is the development of a disease-modifying treatment for atherosclerosis, based on a new class of compounds known as cyclodextrins. With multiple successful funding rounds, including Series Seed I and II, Cyclarity Therapeutics is well-positioned to continue their groundbreaking work. They are set to launch in June 2022, committed to further advancing their technology to treat, cure, and even reverse atherosclerosis.

Formerly known as Underdog Pharmaceuticals, Cyclarity Therapeutics is poised for success in the field of age-related disease treatment